drugset / Trial / NCT00972426

A Study to Evaluate Efficacy and Safety Effects Using Mikelan® LA Ophthalmic Solution (OS) 2% Versus Timoptol® XE Ophthalmic Solution (OS) 0.5% in Ocular Hypertension Patients

NCT00972426

Phase 4 Completed 32 enrolled Taiwan Otsuka Pharm. Co., Ltd
RandomizedParallel-groupOpen-labelTreatment

Summary

The primary objective of the clinical study is to evaluate the efficacy and safety for Mikelan LA eye drops 2% (once per day) of intra-ocular pressure decreased.

Timeline

Start
2009-10
Primary completion
2010-08
Completion
2010-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Carteolol Small molecule 2 % Topical
Subject Timolol Other / unclassified 0.5 % Topical
Background Latanoprost Small molecule

Indications